Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: Shanghai Institute Of Biological Products
This phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss of follow-up.
This description comes directly from the study's public registry record.
Dandan Chen, Master · 86-021-62800991 · ddchen.sh@sinopharm.com
Ye Guo, Doctor · 86-13501678472 · pattrickguo@gmail.com
Always discuss trial participation with your own doctor first.
| Shanghai East Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai East Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06194656